Jennifer L Allen, 58Newport Beach, CA

7854934, Dec 21, 2010

Jul 31, 2002

10/209618

Samuel J. Danishefsky - Englewood NJ, US
Don M. Coltart - New York NY, US
Stacy J. Keding - New York NY, US
Kaustav Biswas - Thousand Oaks CA, US
Philip O. Livingston - New York NY, US
Jennifer R. Allen - Indianapolis IN, US
Lawrence Williams - Edison NJ, US

Sloan-Kettering Institute For Cancer Research - New York NY

A01N 43/04
A61K 39/385
A61K 31/70
A61K 31/715

4241931, 514 8, 514 23, 514 25, 514 42, 514 53, 514 54, 514 62, 530322, 5361231

The present invention provides novel glycosides and glycoconjugates, glycoamino acids, and methods for the synthesis thereof. In another aspect, the present invention provides novel clustered glycopeptides and methods for the synthesis thereof. In still another aspect, the present invention provides methods for the treatment of cancer, preferably for the prevention of recurrence of cancer, and methods for inducing antibodies in a subject, comprising administering to a subject in need, an effective amount of any of the inventive glycopeptides as disclosed herein, either in conjugated form or unconjugated and in combination with a suitable immunogenic carrier.

7879335, Feb 1, 2011

Aug 18, 2000

09/641742

Samuel J. Danishefsky - Englewood NJ, US
Jennifer R. Allen - Indianapolis IN, US
Philip O. Livingston - New York NY, US
Lawrence Williams - New York NY, US

Sloan-Kettering Institute For Cancer Research - New York NY

A01N 43/04
A61K 39/385
A61K 31/70
A61K 31/715

4241931, 514 8, 514 23, 514 25, 514 42, 514 53, 514 54, 514 62, 530322, 5361231

The present invention provides novel n-alkenyl glycosides and glycoconjugates, n-alkyl glycoamino acids, and methods for the synthesis thereof. In another aspect, the present invention provides novel clustered glycopeptides and methods for the synthesis thereof. In still another aspect, the present invention provides methods for the treatment of cancer, preferably for the prevention of recurrence of cancer, and methods for inducing antibodies in a subject, comprising administering to a subject in need, an effective amount of any of the inventive glycoconjugates as disclosed herein.

8623378, Jan 7, 2014

Jan 31, 2011

13/018249

Samuel J. Danishefsky - Englewood NJ, US
Jennifer R. Allen - Indianapolis IN, US
Philip O. Livingston - New York NY, US
Lawrence Williams - New York NY, US

Sloan-Kettering Institute for Cancer Research - New York NY

A01N 43/04
A61K 39/385
A61K 31/70
A61K 31/715

4241931, 4241941, 514 193, 514 23, 514 25, 514 42, 514 53, 514 54, 514 62, 530322, 5361231

The present invention provides novel n-alkenyl glycosides and glycoconjugates, n-alkyl glycoamino acids, and methods for the synthesis thereof. In another aspect, the present invention provides novel clustered glycopeptides and methods for the synthesis thereof. In still another aspect, the present invention provides methods for the treatment of cancer, preferably for the prevention of recurrence of cancer, and methods for inducing antibodies in a subject, comprising administering to a subject in need, an effective amount of any of the inventive glycoconjugates as disclosed herein.

2016028, Sep 29, 2016

Nov 4, 2015

14/932787

- Thousand Oaks CA, US
Jonathan D. LOW - Reseda CA, US
Jennifer R. ALLEN - Newbury Park CA, US
Albert AMEGADZIE - Moorpark CA, US
James BROWN - Moorpark CA, US
Michael J. FROHN - Thousand Oaks CA, US
Angel GUZMAN-PEREZ - Belmont MA, US
Paul E. HARRINGTON - Camarillo CA, US
Patricia LOPEZ - Woodland Hills CA, US
Vu Van MA - Oak Park CA, US
Nobuko NISHIMURA - West Hills CA, US
Wenyuan QIAN - Newbury Park CA, US
Shannon RUMFELT - Camarillo CA, US
Robert M. RZASA - Ventura CA, US
Kelvin SHAM - Thousand Oaks CA, US
Adrian L. SMITH - Simi Valley CA, US
Ryan WHITE - Somerville MA, US
Qiufen XUE - Newbury Park CA, US

AMGEN INC. - Thousand Oaks CA

C07D 413/12

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I:wherein variables A, A, A, A, each of R, R, R, R, Rand Rof Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

2015025, Sep 10, 2015

Apr 21, 2015

14/691715

- Thousand Oaks CA, US
Jonathan D. LOW - Reseda CA, US
Jennifer R. ALLEN - Newbury Park CA, US
Albert AMEGADZIE - Moorpark CA, US
James BROWN - Moorpark CA, US
Michael J. FROHN - Thousand Oaks CA, US
Angel GUZMAN-PEREZ - Belmont MA, US
Paul E. HARRINGTON - Camarillo CA, US
Patricia LOPEZ - Woodland Hills CA, US
Vu Van MA - Oak Park CA, US
Nobuko NISHIMURA - West Hills CA, US
Wenyuan QIAN - Newbury Park CA, US
Shannon RUMFELT - Camarillo CA, US
Robert M. RZASA - Ventura CA, US
Kelvin SHAM - Thousand Oaks CA, US
Adrian L. SMITH - Simi Valley CA, US
Ryan WHITE - Somerville MA, US
Qiufen XUE - Newbury Park CA, US

C07D 265/12
C07D 413/04
C07D 413/10
C07D 413/14
C07D 417/12
C07D 417/14
C07D 413/12
C07D 471/04

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I:wherein variables A, A, A, A, each of R, R, R, R, Rand Rof Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

2014027, Sep 18, 2014

Mar 6, 2014

14/199844

- Thousand Oaks CA, US
Jonathan D. LOW - Tarzana CA, US
Jennifer R. ALLEN - Newbury Park CA, US
Albert AMEGADZIE - Moorpark CA, US
James BROWN - Moorpark CA, US
Michael J. FROHN - Thousand Oaks CA, US
Angel GUZMAN-PEREZ - Belmont MA, US
Paul E. HARRINGTON - Camarillo CA, US
Patricia LOPEZ - Woodland Hills CA, US
Vu Van MA - Oak Park CA, US
Nobuko NISHIMURA - West Hills CA, US
Wenyuan QIAN - Newbury Park CA, US
Shannon RUMFELT - Camarillo CA, US
Robert M. RZASA - Ventura CA, US
Kelvin SHAM - Thousand Oaks CA, US
Adrian L. SMITH - Simi Valley CA, US
Ryan WHITE - Somerville MA, US
Qiufen XUE - Newbury Park CA, US

C07D 471/04
C07D 265/12
C07D 417/12
C07D 417/14
C07D 413/12
C07D 413/14

5142305, 544 90

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I:wherein variables A, A, A, A, each of R, R, R, R, Rand Rof Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

2014024, Sep 4, 2014

Feb 27, 2014

14/192710

- Thousand Oaks CA, US
Jonathan D. LOW - Tarzana CA, US
Jennifer R. ALLEN - Newbury Park CA, US
Jian CHEN - Camarillo CA, US
Ning CHEN - Thousand Oaks CA, US
Yuan CHENG - Newbury Park CA, US
Ted JUDD - Granada Hills CA, US
Qingyian LIU - Camarillo CA, US
Patricia LOPEZ - Woodland Hills CA, US
Wenyuan QIAN - Newbury Park CA, US
Shannon RUMFELT - Camarillo CA, US
Robert M. RZASA - Ventura CA, US
Nuria A. TAMAYO - Newbury Park CA, US
Qiufen XUE - Newbury Park CA, US
Bryant YANG - Agoura Hills CA, US
Wenge ZHONG - Thousand Oaks CA, US

C07D 413/14
C07F 7/08
C07D 513/04
C07D 413/12
C07D 471/04

514 63, 544 96, 5142288, 544 69

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I:wherein variables A, A, A, A, each of Rand R, Rand Rof Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.